Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Completed · Phase 3 · NCT02898454
Conditions: Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
At a glance
- Research payments reported, 2025
- $750
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 448
About the trial
- Sponsor
- Sanofi (with Regeneron Pharmaceuticals)
- Tested
- Dupilumab SAR231893 (REGN668) (drug), Placebo (drug), Mometasone furoate nasal spray (drug)
- Dates
- Started 2016-11-28; completion 2018-11-16
- Results posted
- Yes
Primary Objective: To evaluate the efficacy of dupilumab 300 mg every 2 weeks (q2w) compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion (NC)/obstruction severity and endoscopic nasal polyp score (NPS) in participants with bilateral nasal polyps (NP). In addition for Japanese participants, reduction in computed tomography (CT) scan opacification of the sinuses was a co-primary objective. Secondary Objectives: * To evaluate the efficacy of dupilumab in improving total symptoms score. * To evaluate the efficacy of dupilumab in improving sense of smell. * To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuse…
From ClinicalTrials.gov, last updated 2019-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $750 in research payments for this study in 2025 (2 payments).
Products named: Dupixent
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $750
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.